Experiences in the treatment of advanced hepatocellular carcinoma (HCC) with sorafenib beyond the SHARP trial–Patients with liver cirrhosis Child Pugh B/C and after liver transpla…
MA Wörns, H Schulze-Bergkamen, H Schulze-Bergkamen, M Schuchmann, M Schuchmann, C Düber, C Düber, G Otto, G Otto, PR Galle, PR Galle, A Weinmann · Zeitschrift für Gastroenterologie · 2008 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: Patients (pts) with advanced hepatocellular carcinoma (HCC) not eligible for curative treatments such as resection or liver transplantation have a dismal prognosis with survival rates less than six months. Sorafenib (Nexavar®, Bayer Health Care, Germany), a novel multikinase inhibitor blocking tumor cell proliferation and angiogenesis, was recently shown to provide a survival benefit in Child-Pugh A pts with advanced HCC (SHARP trial). Here, we report about our experiences with sorafenib in the treatment of advanced HCC beyond the SHARP trial in pts with Child Pugh B/C liver cirrhosis (LCI) and after ortho…
